Department of Hepatobiliary and Pancreatovascular Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
BMC Gastroenterol. 2021 Jun 6;21(1):248. doi: 10.1186/s12876-021-01831-4.
Signet ring cell carcinoma (SRC) is a rare histological subtype of gallbladder adenocarcinoma. The current study evaluates the clinicopathologic features and prognosis of SRC.
Patients with adenocarcinoma of the gallbladder were identified in the Surveillance, Epidemiology, and End Results database from 1973 to 2016. Overall survival (OS) and cancer-specific survival (CSS) of patients who had SRC were compared with those of patients who had non-SRC using Cox regression and propensity score methods.
Of 22,781 gallbladder adenocarcinomas retrieved, 377 (1.7%) were SRC and the other 22,404 were non-SRC. SRC was more significantly associated with older age, female gender, poor differentiation, advanced tumor stage, lymph node metastasis, distant metastasis, and advanced AJCC stage. The 5-year OS and CSS in the SRC group were 7.2 and 6.5%, respectively, both of which were significantly worse than the 13.2 and 13.3% seen in the SRC group (P = 0.002 and P = 0.012, respectively). This survival disadvantage persisted in multivariable analyses [hazard ratio (HR) = 1.256, P = 0.021 and HR = 1.211, P = 0.036] and after propensity score matching (OS: HR = 1.341, P = 0.012 and CSS: HR = 1.625, P = 0.005). Surgery in combination with chemotherapy improved OS of gallbladder SRC patients compared with surgery alone (HR = 0.726, P = 0.036) or chemotherapy alone (HR = 0.433, P < 0.001).
Patients with SRC of the gallbladder have distinct clinicopathological features with poor prognosis. Surgery in combination with chemotherapy can improve survival.
印戒细胞癌(SRC)是胆囊腺癌的一种罕见组织学亚型。本研究评估了 SRC 的临床病理特征和预后。
从 1973 年到 2016 年,在监测、流行病学和最终结果数据库中确定了胆囊腺癌患者。使用 Cox 回归和倾向评分方法比较了具有 SRC 的患者与具有非-SRC 的患者的总生存(OS)和癌症特异性生存(CSS)。
在 22781 例胆囊腺癌中,有 377 例(1.7%)为 SRC,其余 22404 例为非-SRC。SRC 与年龄较大、女性、分化差、肿瘤分期较晚、淋巴结转移、远处转移和 AJCC 分期较晚显著相关。SRC 组的 5 年 OS 和 CSS 分别为 7.2%和 6.5%,均明显低于 SRC 组的 13.2%和 13.3%(P=0.002 和 P=0.012)。这种生存劣势在多变量分析中仍然存在[风险比(HR)=1.256,P=0.021 和 HR=1.211,P=0.036],并且在倾向评分匹配后仍然存在(OS:HR=1.341,P=0.012 和 CSS:HR=1.625,P=0.005)。与单独手术或单独化疗相比,手术联合化疗可改善胆囊 SRC 患者的 OS(HR=0.726,P=0.036)或单独化疗(HR=0.433,P<0.001)。
胆囊 SRC 患者具有明显的临床病理特征和不良预后。手术联合化疗可以提高生存率。